US Stock MarketDetailed Quotes
IBIO iBio Inc
- 2.8300
- -0.0100-0.35%
Close Jan 17 16:00 ET
- 2.8600
- +0.0300+1.06%
Post 18:31 ET
26.57MMarket Cap-1.31P/E (TTM)
2.8500High2.6700Low121.97KVolume2.8300Open2.8400Pre Close340.87KTurnover1.43%Turnover RatioLossP/E (Static)9.39MShares4.980052wk High1.50P/B24.16MFloat Cap1.030052wk Low--Dividend TTM8.54MShs Float30300.0000Historical High--Div YieldTTM6.34%Amplitude1.0214Historical Low2.7940Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
iBio Inc Stock Forum
📊⚡️📊
LFGGGG
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Tuesday, 7th January at 7:00 am
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.(NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio's patented Machine-L...
Benzinga· 3 mins ago
iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially best-in-class long-acting anti-myostatin antibody from AstralBio, Inc. The antibody, now named IBIO-600, was identified by AstralBio using iBio's proprieta...
No comment yet